Marker Therapeutics, Inc.

Monthly Archives: June 2013

TapImmune Chairman Provides Corporate Update on Development Programs & Collaborations

It is my pleasure to provide an update to existing and potentially new shareholders on the progress we have made over the past few months. Highlights from the below detailed update include: Positive progress at the MAYO clinic on the phase 1 HER2/neu clinical trial with interim results expected in the near term.
Read More